Wednesday, March 11, 2026 3/11/2026

Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding

Award Number: R44HL176351
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding - ABSTRACT The objective of this proposal is to optimize and validate the hemostatic bioadhesive paste in compliance with FDA regulatory guidance for the FDA IDE approval in advance of the future pivotal clinical trial and ultimate regulatory clearance and commercialization. In light of the huge and rapidly growing clinical and economic costs of major hemorrhagic events in cardiovascular and other surgeries, various hemostatic agents have been developed and clinically tested. To date, however, there is no hemostatic solution that can achieve effective and rapid hemostasis in frequent and high-risk bleeding of patients under anticoagulation or coagulopathic settings due to the incompatibility of conventional coagulation-based hemostatic approaches. To address these limitations of existing solutions, during the prior development (Phase I-equivalent), our collaborative team developed a proof-of-concept prototype of a hemostatic bioadhesive paste for rapid (within 10 s) coagulation- independent control of bleedings by uniquely utilizing the novel blood-resistant bioadhesive mechanism. The preliminary pre-clinical validation and analysis based on in vivo rat and porcine models demonstrated the promising hemostatic efficacy and underlying mechanism of the hemostatic bioadhesive paste for the bioadhesion-based coagulation-independent rapid control of bleedings. Building upon the promising outcome of the prior development, under the scope of this Direct-to-Phase II SBIR proposal, we will further optimize and validate the hemostatic bioadhesive paste in compliance with relevant FDA regulatory guidance for the highly effective and broadly affordable solution to treat high-risk bleeding in the anticoagulated or coagulopathic patients. If successful, the proposed project will allow SanaHeal to prepare and submit the FDA IDE package in advance to a pivotal clinical trial and ultimate commercialization with far-reaching benefits for patients and the healthcare system.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,249,317 )
2025	2025	SANAHEAL INC	100 CHESTNUT ST STE 300	SOMERVILLE	MA	02143	MIDDLESEX	USA	Blood Diseases and Resources Research	000	2	9/15/2025	NON-COMPETING CONTINUATION	$1,249,317
														Subtotal = $1,249,317

Issue Date FY: 2024 ( Subtotal = $1,249,317 )
2024	2024	SANAHEAL INC	363 MARLBOROUGH ST	BOSTON	MA	02115	SUFFOLK	USA	Blood Diseases and Resources Research	000	1	9/24/2024	NEW	$1,249,317
														Subtotal = $1,249,317

Grand Total All Awards = $2,498,634

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding

Award Number: R44HL176351

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer